*Titles, times, and locations may change. Check SABCS.org or the SABCS meeting platform and mobile app for the latest schedule.
GENERAL SESSION 2
Thursday, December 7
8:15 a.m. – 11:15 a.m.
Hall 1
8:15–8:30 a.m. —GS02-01: Randomized phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer: Results from TROPION-Breast01
8:30–8:45 a.m. —GS02-02: Are nodal ITCs after neoadjuvant chemotherapy an indication for axillary dissection? The OPBC05/EUBREAST-14R/ICARO study
8:45–9:00 a.m. —GS02-03: Discussant for GS02-02
9:00–9:15 a.m. —GS02-04: Surgical treatment of women with breast cancer and a BRCA1 mutation: An international analysis of the impact of bilateral mastectomy on survival
9:15–9:30 a.m. —GS02-05: Overview of axillary treatment in early breast cancer: Patient-level meta-analysis of long-term outcomes among 20,273 women in 29 randomized trials
9:30–9:45 a.m. —GS02-06: Recurrence-free survival following sentinel node-positive breast cancer without completion axillary lymph node dissection: First results from the international randomized SENOMAC trial
9:45–10:00 a.m. —GS02-07: Loco-regional irradiation in patients with biopsy-proven axillary node involvement at presentation who become pathologically node-negative after neoadjuvant chemotherapy: Primary outcomes of NRG oncology/NSABP B-51/RTOG 1304
10:00–10:15 a.m. —GS02-08: Five-year outcomes of the IDEA trial of endocrine therapy without radiotherapy after breast-conserving surgery for postmenopausal patients age 50-69 with genomically selected favorable Stage I breast cancer
10:15–10:30 a.m. —GS02-09: Discussant for GS02-06, GS02-07, and GS02-08
10:30–10:45 a.m. —GS02-10: Effects of a structured and individualized exercise program on fatigue and health-related quality of life in patients with metastatic breast cancer: the multinational randomized controlled PREFERABLE-EFFECT study
10:45–11:00 a.m. —GS02-11: Fertility preservation and assisted reproductive technologies (ART) in breast cancer (BC) patients (pts) interrupting endocrine therapy (ET) to attempt pregnancy
11:00–11:15 a.m. – GS02-12: Discussant for GS02-11
POSTER SPOTLIGHT SESSION #10: REFINING PREDICTION OF CANCER RISK AND OUTCOMES
7:00 a.m. – 8:00 a.m.
Stars at Night Ballroom 3-4
Presentations:
PS10-01: Hormonal contraception and breast cancer risk for carriers of germline pathogenic variants in BRCA1 and BRCA2
PS10-02: Association between germline mutation status and overall survival among women with breast cancer in population-based studies in the United States
PS10-03: Impact of baseline oestradiol and testosterone on the preventive effect of anastrozole
PS10-04: The landscape of somatic genetic alterations in breast cancers from carriers of germline pathogenic variants in DNA-repair genes
PS10-05: Discussant and panel discussion
PS10-06: Contribution of a breast cancer polygenic risk score to mammography artificial intelligence models and breast density for long term breast cancer risk prediction
PS10-07: A second-generation polygenic risk score PRS based on genetic ancestry improves breast cancer BC risk prediction for all ancestries
PS10-08: Validation of a clinical image-based AI-risk model for individualized breast cancer screening in a multi-national setting
PS10-09: Development of an absolute risk prediction model for premenopausal breast cancer in an international consortium
PS10-10: Discussant and panel discussion
POSTER SPOTLIGHT SESSION #11: CNS DISEASE IN BREAST CANCER: WHERE ARE WE NOW AND CAN WE DO BETTER?
7:00 a.m. – 8:00 a.m.
Hemisfair Ballroom 1-2
Presentations:
PS11-01: Brain metastases in metastatic breast cancer: prevalence per line of treatment and cumulative incidence in a cohort of 18075 real-world patients
PS11-02: Clinical risk factors of Central Nervous System CNS-related death in patients with HER2-positive metastatic breast cancer
PS11-03: Comparison of next-generation sequencing NGS results from the cerebrospinal fluid, peripheral blood, and systemic metastatic tumor tissue of patients with metastatic breast cancer MBC and leptomeningeal disease LMD
PS11-05: Trastuzumab deruxtecan in patients with HER2[+] or HER2-low advanced breast cancer and pathologically confirmed leptomeningeal carcinomatosis: Results from cohort 5 of the DEBBRAH study
PS11-06: Analysis of HER2 expression changes from breast primary to brain metastases including HER2 Low and impact on overall survival
PS11-07: High prevalence of HER2-Low and AR expression in breast cancer brain metastases provide novel therapeutic options
PS11-08: Discussant and panel discussion
POSTER SPOTLIGHT SESSION #12: PUTTING BRAKES ON THE CELL CYCLE: UNDERSTANDING MECHANISMS GOVERNING CDK 4/6 INHIBITOR RESISTANCE AND ROLE FOR NOVEL THERAPEUTIC STRATEGIES
7:00 a.m. – 8:00 a.m.
Stars at Night Ballroom 1-2
Presentations:
PS12-02: Exploration of ctDNA Dynamics in the PACE trial: A randomized phase ii study of fulvestrant, palbociclib, and avelumab for HR+/HER2- metastatic breast cancer
PS12-03: p53 loss enables HR+ breast cancer escape from CDK4/6 inhibitor-induced quiescence via CDK2
PS12-04: Inhibition of GPX4 enhances CDK4/6 inhibitor activity in breast cancer.
PS12-05: Discussant and panel discussion
PS12-06: A phase 2 study of abemaciclib monotherapy for patients with retinoblastoma-positive (Rb+), triple-negative metastatic breast cancer
PS12-07: Phase II clinical trial of palbociclib and binimetinib in advanced triple-negative breast cancer (TNBC) with hyperactivation of ERK and/or CDK4/6
PS12-08: MORPHEUS hormone receptor-positive breast cancer: interim analysis of a phase Ib/II, study of fulvestrant ± atezolizumab and abemaciclib triplet treatment in patients metastatic disease
PS12-09: Capivasertib plus cyclin-dependent kinase 4/6 inhibitor and fulvestrant in hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: updated Phase 1b analysis from CAPItello-292
PS12-10: Discussant and panel discussion
POSTER SPOTLIGHT SESSION #13: SPECIAL POPULATIONS: PREGNANCY, MALE AND GERIATRIC PATIENTS
5:30 p.m. – 6:30 p.m.
Stars at Night Ballroom 3-4
Presentations:
PS13-01: Worse prognosis for breast cancer in the second and third trimesters and shortly postpartum: An update of the Dutch pregnancy-associated breast cancer cohort
PS13-02: Clinical outcome and patients’ characteristics of breast cancer diagnosed during pregnancy: A retrospective single institutional study
PS13-03: Safety of taxane chemotherapy for the treatment of breast cancer during pregnancy: an international cohort study
PS13-04: Frequent Intra-tumoral hypoxia in pregnancy-associated breast cancer
PS13-05: Pregnancy after breast cancer in young women with germline BRCA pathogenic variants: results from an international cohort study
PS13-06: Discussant and panel discussion
PS13-07: Systemic therapy in geriatric patients with triple negative breast cancer: a National Cancer Database analysis
PS13-08: Chemotherapy in geriatric patients with early stage HER2+ breast cancer: A National Cancer Database analysis.
PS13-09: Molecular and immunological landscape of sex-based differences in breast cancer: a distinct disease in men.
PS13-10: Discussant and panel discussion
POSTER SPOTLIGHT SESSION #14: SETTING EXPECTATIONS FOR TOXICITIES RELATED TO I/O THERAPY
5:30 p.m. – 6:30 p.m.
Hemisfair Ballroom 1-2
Presentations:
PS14-01: Immune related adverse events in patients ≥65 years vs. <65 years with breast cancer treated with immunotherapy
PS14-02: Real-world analysis comparing Black and White patients with triple-negative breast cancer receiving therapy per KEYNOTE-522
PS14-03: Delayed and post-treatment immune toxicities in patients with breast cancer receiving immune checkpoint inhibitors.
PS14-04: Discussant and panel discussion
PS14-05: Safety evaluation from the KEYNOTE-522 study of neoadjuvant pembrolizumab (or placebo) plus chemotherapy followed by adjuvant pembrolizumab (or placebo) in patients with early triple-negative breast cancer (TNBC)
PS14-06: Real-world analysis comparing Black and White patients with triple-negative breast cancer receiving therapy per KEYNOTE-522
PS14-07: Exploring Circulating Leukocyte RNA Expression: Implications for Treatment Outcomes and Immune-Related Adverse Events in Patients with Triple Negative Breast Cancer Enrolled in the GeparNuevo Trial
PS14-08: Safety evaluation from the KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer
PS14-09: Discussant and panel discussion
POSTER SPOTLIGHT SESSION #15: NOVEL NUCLEAR RECEPTOR TARGETING THERAPIES
5:30 p.m. – 6:30 p.m.
Stars at Night Ballroom 1-2
Presentations:
PS15-01: A first-in-human phase 1 study of SIM0270, a brain-penetrant oral selective estrogen receptor degrader (SERD), in patients with ER+/ HER2- locally advanced or metastatic breast cancer
PS15-02: A Phase Ⅰb Study of D-0502 as monotherapy for advanced or metastatic ER-positive and HER2-negative breast cancer: Results from the dose-expansion stage
PS15-03: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib in ER–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: phase 1b cohort
PS15-04: A Phase 1b/2 study of palazestrant (OP-1250), an oral complete estrogen receptor antagonist (CERAN) and selective ER degrader (SERD), with palbociclib in ER-positive, HER2-negative, advanced or metastatic breast cancer patients
PS15-05: Discussant and panel discussion
PS15-06: Results of the window-of-opportunity PIONEER trial evaluating addition of the progesterone receptor (PR) agonist megestrol to letrozole for early stage estrogen receptor (ER) positive breast cancer: exploiting ER-PR interaction
PS15-07: Proxalutamide plus Endocrine Therapies in Women with HR+/HER2-/AR+ Metastatic Breast Cancer: A Phase Ic Study
PS15-08: Final Overall Survival (OS) analysis of the SAKK 21/12 trial. CR1447 in HR+/HER2- metastatic breast cancer and androgen receptor positive triple negative breast cancer.
PS15-09: Imlunestrant monotherapy and in combination with abemaciclib, with or without an aromatase inhibitor, in estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC): updated results from the EMBER study
PS15-10: Discussant and panel discussion
